KYMR
Kymera Reports Q3 2026 Results, Positive Data for KT-579
Kymera Therapeutics released Q3 2026 financial results, highlighting positive Phase 1 data for KT-579 and updated clinical trial timelines for its degrader portfolio.
KYMR news
Latest 5 stories · newest Oct 29, 2026
KYMR
KYMR
Kymera completes STAT6 trial early; raises cash runway
Kymera Therapeutics reported enrollment for the KT-621 AD trial completed ahead of schedule and completed the quarter with $1.5 billion in cash, extending runway through 2029. The advancement is meaningful for the pipeline but has limited immediate impact on current market value.
KYMR
Kymera Appoints Terence Rooney MD as Chief Medical Officer
Kymera Therapeutics appointed immunology leader Dr. Terence Rooney as Chief Medical Officer to lead clinical development, succeeding Dr. Jared Gollob, who is retiring.
KYMR
Kymera completes Phase 2b enrollment for atopic dermatitis candidate KT-621
Kymera finished enrollment early for the Phase 2b BROADEN2 trial for atopic dermatitis candidate KT-621, accelerating data timelines to year-end 2026. The early success supports the company's plan to initiate Phase 3 trials in mid-2027 following regulatory review.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same KYMR feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/KYMR/newsSTART FREE